Perindopril Erbumine

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Coversum; Belgium: Coversyl; Bulgaria: Coverex; Denmark: Coversyl; Estonia: Prenessa; Finland: Coversyl; France: Coversyl; Germany: Coversum; Greece: Coversyl; Hungary: Coverex; Ireland: Coversyl; Italy: Coversyl; Luxembourg: Coversyl; Netherlands: Coversyl; Poland: Coverex, Peryndopryl; Portugal: Coversyl; Spain: Perindopril; Sweden: Coverex; UK: Coversyl.

North America

Canada: Coversyl, Perindopril; USA: Aceon.

Latin America

Argentina: Coverene; Brazil: Coversyl; Mexico: Coversyl.


Japan: Cobathrow, Coversyl, Perindopril, Perinsyl.

Drug combinations

Perindopril Erbumine and Amlodipine

Perindopril Erbumine and Indapamide


Perindopril Erbumine: C~19~H~32~N~2~O~5~ C~4~H~11~N. Mw: 441.60. (1) 1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2α,3aβ,7aβ]]-, compd. with 2-methyl-2-propanamine (1:1); (2)(2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester, compound with tert-butylamine (1:1). CAS-107133-36-8 (1989).

Pharmacologic Category

Angiotensin-Converting Enzyme Inhibitors. (ATC-Code: C09AA04).

Mechanism of action

A prodrug for perindoprilat, which acts as competitive inhibitor of angiotensin-converting enzyme. Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, and causes increase in plasma renin activity and reduction in aldosterone secretion.

Therapeutic use

Treatment of hypertension. Reduction of cardiovascular mortality or nonfatal myocardial infarction in stable coronary artery disease.

Pregnancy and lactiation implications

Adverse events observed in humans. Perindopril crosses placenta. ACE inhibitors can cause injury and death to developing fetus. ACEIs should be discontinued as soon as possible once pregnancy is detected. Excretion in breast milk unknown (caution when administering perindopril to nursing women).

Unlabeled use

To delay progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus.


Hypersensitivity to perindopril, any other ACEI, or any component of the formulation. Angioedema related to previous treatment with ACEI.

Warnings and precautions

Angioedema may occur rarely with ACEIs (may involve head and neck or intestine). African-Americans and patients with idiopathic or hereditary angioedema may be at increased risk. Patients with history of airway surgery may have higher risk of airway obstruction. Use in previous angioedema associated with ACEI therapy contraindicated. Cholestatic jaundice, which may progress to fulminant hepatic necrosis, may occur. A dry, hacking, nonproductive cough usually occurs within first few months of treatment (should generally resolve within 1-4 weeks after discontinuation of ACEI). Hyperkalemia may occur with ACEIs (risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts). Anaphylactic/anaphylactoid reactions can occur with ACEIs. Symptomatic hypotension with or without syncope can occur (usually with first several doses). Another ACEI, captopril, associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (e.g. systemic lupus erythematosus) are at even higher risk of developing neutropenia. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in low renal blood flow (e.g. renal artery stenosis, heart failure) whose glomerular filtration rate is dependent on efferent arteriolar vasoconstriction by angiotensin II. Use with caution in severe aortic stenosis (may reduce coronary perfusion resulting in ischemia). Caution in cardiovascular disease (ischemic heart disease or cerebrovascular) due to potential consequences posed by falling blood pressure (e.g. MI, stroke). Use with caution in collagen vascular disease, especially with concomitant renal impairment (may be at increased risk for hematologic toxicity). Use with caution in hypertrophic cardiomyopathy and outflow tract obstruction (reduction in afterload may worsen symptoms). Use with caution in unstented unilateral/bilateral renal artery stenosis, and in pre-existing renal insufficiency. ACEIs can cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters. Use with caution before, during, or immediately after major surgery (use of ACEIs perioperatively will blunt angiotensin II formation and may result in hypotension).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart